RT Journal Article
SR Electronic
T1 Hypertension and renin-angiotensin system blockers are not associated with expression of Angiotensin Converting Enzyme 2 (ACE2) in the kidney
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20106781
DO 10.1101/2020.05.19.20106781
A1 Xiao Jiang
A1 James Eales
A1 David Scannali
A1 Alicja Nazgiewicz
A1 Priscilla Prestes
A1 Michelle Maier
A1 Matthew Denniff
A1 Xiaoguang Xu
A1 Sushant Saluja
A1 Eddie Cano-Gamez
A1 Wojciech Wystrychowski
A1 Monika Szulinska
A1 Andrzej Antczak
A1 Sean Byars
A1 Maciej Glyda
A1 Robert Król
A1 Joanna Zywiec
A1 Ewa Zukowska-Szczechowska
A1 Louise M. Burrell
A1 Adrian S. Woolf
A1 Adam Greenstein
A1 Pawel Bogdanski
A1 Bernard Keavney
A1 Andrew P. Morris
A1 Anthony Heagerty
A1 Bryan Williams
A1 Stephen B. Harrap
A1 Gosia Trynka
A1 Nilesh J. Samani
A1 Tomasz J. Guzik
A1 Fadi J. Charchar
A1 Maciej Tomaszewski
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106781.abstract
AB Angiotensin converting enzyme 2 (ACE2) is the cellular entry point for severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the cause of COVID-19 disease. It has been hypothesized that use of renin-angiotensin system (RAS) inhibiting medications in patients with hypertension, increases the expression of ACE2 and thereby increases the risk of COVID-19 infection and severe outcomes or death. However, the effect of RAS-inhibition on ACE2 expression in human tissues of key relevance to blood pressure regulation and COVID-19 infection has not previously been reported.We examined how hypertension, its major metabolic co-phenotypes and antihypertensive medications relate to ACE2 renal expression using information from up to 436 patients whose kidney transcriptomes were characterised by RNA-sequencing. We further validated some of the key observations in other human tissues and/or a controlled experimental model. Our data reveal increasing expression of ACE2 with age in both human lungs and the kidney. We show no association between renal expression of ACE2 and either hypertension or common types of RAS inhibiting drugs. We demonstrate that renal abundance of ACE2 is positively associated with a biochemical index of kidney function and show a strong enrichment for genes responsible for kidney health and disease in ACE2 co-expression analysis.Collectively, our data indicate that neither hypertension nor antihypertensive treatment are likely to alter individual risk of SARS-CoV-2 infection or influence clinical outcomes in COVID-19 through changes of ACE2 expression. Our data further suggest that in the absence of SARS-CoV-2 infection, kidney ACE2 is most likely nephro-protective but the age-related increase in its expression within lungs and kidneys may be relevant to the risk of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by British Heart Foundation project grants PG/17/35/33001 and PG/19/16/34270 and Kidney Research UK grant RP_017_20180302 to MT, British Heart Foundation Personal Chair CH/13/2/30154 and Manchester Academic Health Science Centre: Tissue Bank Grant to BK, Medical University of Silesia grants KNW-1-152/N/7/K to JZ and KNW-1-171/N/6/K to WW. LMB acknowledges support from National Health and Medical Research Council Program Grant (APP1055214) and Medical Research Future Fund (APP 1175865). Access to TCGA kidneys and GTEx data has been granted by NIH (approvals 50804-2 and 50805-2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSelective data are available upon request.